Unichem Laboratories Limited Stock Price Today (NSE: UNICHEMLAB)
Fundamental Score
Unichem Laboratories Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Unichem Laboratories Limited share price today is ₹526.05, down 0.67% on NSE/BSE as of 25 August 2026. Unichem Laboratories Limited (UNICHEMLAB) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹4.18K (Cr). The 52-week high for UNICHEMLAB share price is ₹555.95 and the 52-week low is ₹278.20. 0
Unichem Laboratories Limited Share Price Chart — NSE/BSE Historical Performance
Unichem Laboratories Limited share price chart: 0.00% return over the past month. 52-week high ₹555.95, 52-week low ₹278.20.
Unichem Laboratories Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹510.05 | ₹555.95 | ₹504.05 | ₹526.05 | 8.19L (Cr) | |
| ₹548.80 | ₹552.90 | ₹521.60 | ₹529.60 | 1.20L (Cr) | |
| ₹345.30 | ₹368.40 | ₹345.05 | ₹364.90 | 89.04K (Cr) | |
| ₹353.00 | ₹358.35 | ₹339.50 | ₹343.05 | 14.08K (Cr) | |
| ₹351.15 | ₹363.30 | ₹346.35 | ₹349.35 | 16.43K (Cr) | |
| ₹361.55 | ₹361.65 | ₹353.10 | ₹354.55 | 11.66K (Cr) | |
| ₹360.00 | ₹363.55 | ₹354.00 | ₹356.20 | 27.37K (Cr) | |
| ₹361.05 | ₹366.45 | ₹349.95 | ₹359.50 | 99.23K (Cr) | |
| ₹371.65 | ₹379.65 | ₹364.65 | ₹370.85 | 41.15K (Cr) | |
| ₹377.95 | ₹379.05 | ₹362.20 | ₹367.15 | 28.19K (Cr) |
Unichem Laboratories Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹548.80 | ₹555.95 | ₹504.05 | ₹526.05 | -4.15% | |
| ₹353.00 | ₹368.40 | ₹339.50 | ₹364.90 | +3.37% | |
| ₹390.10 | ₹398.80 | ₹346.35 | ₹349.35 | -10.45% | |
| ₹292.10 | ₹402.00 | ₹291.30 | ₹390.10 | +33.55% | |
| ₹316.00 | ₹348.25 | ₹278.20 | ₹293.45 | -7.14% | |
| ₹373.30 | ₹445.25 | ₹343.10 | ₹346.20 | -7.26% | |
| ₹440.10 | ₹445.95 | ₹361.05 | ₹374.35 | -14.94% | |
| ₹468.85 | ₹475.65 | ₹429.55 | ₹441.85 | -5.76% | |
| ₹470.00 | ₹499.40 | ₹444.00 | ₹467.15 | -0.61% | |
| ₹460.10 | ₹494.00 | ₹459.10 | ₹470.95 | +2.36% | |
| ₹503.80 | ₹515.00 | ₹455.55 | ₹461.40 | -8.42% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Unichem Laboratories Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Unichem Laboratories Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of UNICHEMLAB across key market metrics for learning purposes.
Positive Indicators
8 factors identified
Strong Revenue Growth (20.13%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (12.26% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (49.06% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Conservative Debt Levels (D/E: 0.17)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (10.26x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Healthy Liquidity Position (Current Ratio: 2.48)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Balanced Promoter Holding (70.22%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
3 factors identified
Below-Average Return on Equity (0.00%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Negative Free Cash Flow (₹-788.35 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Unichem Laboratories Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Unichem Laboratories Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Unichem Laboratories LimitedUnichem Laborat...Selected✓ UNICHEMLAB • 506690 | 35.1/100 | ₹526.05₹526 | ₹4183.01₹4183.01 | — — | 0.00%Poor 0.00% Poor | 11.93%Average 11.93% Average | 0.17Excellent 0.2 Excellent | — — | 12.26%Good 12.26% Good | 0.00% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1875.10₹1875 | ₹468821.49₹468821.49 | 38.76Average 38.8 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹8588.00₹8588 | ₹193163.97₹193163.97 | 66.04Average 66.0 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4971.00₹4971 | ₹169902.02₹169902.02 | 77.90Average 77.9 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1431.10₹1431 | ₹116131.81₹116131.81 | 34.45Average 34.5 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1115.60₹1116 | ₹115375.77₹115375.77 | 25.57Average 25.6 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2232.00₹2232 | ₹113976.53₹113976.53 | 20.62Average 20.6 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2380.00₹2380 | ₹105053.91₹105053.91 | 51.28Average 51.3 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | — — | — — | 0.04% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1178.80₹1179 | ₹102660.46₹102660.46 | 31.86Average 31.9 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1645.00₹1645 | ₹90035.87₹90035.87 | 24.25Average 24.3 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1814.00₹1814 | ₹84016.75₹84016.75 | 76.84Average 76.8 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | — — | 7.19%Good 7.19% Good | 0.13% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price468821.49 Cr
- Divi's Laboratories Limited share price193163.97 Cr
- Torrent Pharmaceuticals Limited share price169902.02 Cr
- Cipla Limited share price116131.81 Cr
- Zydus Lifesciences Limited share price115375.77 Cr
Unichem Laboratories Limited PE Ratio History
Historical price-to-earnings ratio for UNICHEMLAB — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹19.47 | ₹441.85 | 22.7x |
| FY 2022 | ₹4.68 | ₹315.60 | 67.4x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Unichem Laboratories Limited Dividend History
Annual cash dividends paid by UNICHEMLAB — dividend yield N/A
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹0.34 Cr |
| FY 2024 | ₹0.21 Cr |
| FY 2023 | ₹28.25 Cr |
| FY 2022 | ₹28.36 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Unichem Laboratories Limited Quarterly Performance
Latest quarterly metrics for UNICHEMLAB — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
20.13%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
N/A
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
12.26%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
N/A
Compounded annual net profit growth over 5 years
Unichem Laboratories Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for UNICHEMLAB — calculated from daily price history
Momentum is strong — price may be stretched. Watch for pullbacks.
Technical indicators are for educational purposes only. Not investment advice.
Unichem Laboratories Limited Financial Statements
Annual income statement, balance sheet and cash flow for Unichem Laboratories Limited (UNICHEMLAB) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Unichem Laboratories Limited
About UNICHEMLAB (Unichem Laboratories Limited)
Unichem Laboratories Ltd is a well-established Indian pharmaceutical company involved in developing, manufacturing, and marketing a broad range of pharmaceutical products. They ope...rate in both the domestic Indian market and internationally, with a focus on producing finished formulations and active pharmaceutical ingredients (APIs). Their product portfolio covers various therapeutic areas including treatments for heart conditions, diabetes, mental health, and infections, along with pain relief medications. The company's business is broadly divided into formulations, which are the finished medicines sold to patients, and APIs, which are the raw ingredients used to make these medicines. Unichem also provides contract manufacturing services to other pharmaceutical companies. They cater to a diverse customer base including patients, healthcare professionals, distributors, and government institutions, solidifying their presence across the pharmaceutical value chain. Within the Indian pharmaceutical landscape, Unichem holds a significant position, driven by its established brand reputation and wide range of offerings. Although now a subsidiary of Ipca Laboratories, Unichem continues to operate with its own distinct product lines and market strategies, focusing on providing affordable and accessible healthcare solutions to meet the evolving needs of the Indian population and beyond.
Company Details
Key Leadership
Corporate Events
UNICHEMLAB Share Price: Frequently Asked Questions
What is the current share price of Unichem Laboratories Limited?
Unichem Laboratories Limited (UNICHEMLAB) trades at ₹526.05 on NSE and BSE. Market cap ₹4.18K (Cr). Educational data only.
What is the P/E ratio of Unichem Laboratories Limited?
Unichem Laboratories Limited has a P/E of N/Ax vs industry average 34.89x.
What is the Bull Run score for Unichem Laboratories Limited?
Unichem Laboratories Limited has a Bull Run score of 35.1/100 based on 25+ financial parameters.
Does Unichem Laboratories Limited pay dividends?
Unichem Laboratories Limited has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Unichem Laboratories Limited?
Unichem Laboratories Limited has ROE of 0.00%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Unichem Laboratories Limited?
Unichem Laboratories Limited has debt-to-equity of 0.17.
Is Unichem Laboratories Limited a good investment?
Bull Run gives Unichem Laboratories Limited a score of 35.1/100. This is not investment advice — consult a SEBI-registered advisor.